Please login to the form below

Not currently logged in
Email:
Password:

Dr Jan van de Winkel joins Austrian biotech Hookipa

Joins the firm's board of directors, taking up the chairman's role

Dr Van De WinkelAustrian biotech Hookipa has appointed its chairman of the board of directors in the form of Dr Jan van de Winkel.

Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’ experience in the therapeutic antibody field.

He said: “I am honoured to take on the role of chairman at this exciting time in the life of this very promising company and I am looking forward to building the company together with its management team and other board members who have done this very successfully before.”

Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice president and scientific director before co-founding Genmab.

Jorn Aldag, chief executive officer, Hookipa, said: “We are proud to have attracted Jan to join our board of directors as Chairman.

“As Hookipa grows and progresses to become an integrated biotech company with multiple clinical programmes in infectious diseases and immune-oncology, Jan’s experience of building companies and his scientific insight will prove invaluable.”

7th November 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...

Infographics